(Q40923764)

24 September 2017

1 reference

title

Primary progressive multiple sclerosis: a distinct syndrome? (English)

1 reference

primary progressive multiple sclerosis

24 September 2017

0 references

author name string

G V McDonnell

series ordinal

1

1 reference

PubMed ID

9345378

24 September 2017

S A Hawkins

series ordinal

2

1 reference

24 September 2017

1 October 1996

1 reference

Multiple Sclerosis Journal

24 September 2017

1 reference

24 September 2017

2

1 reference

24 September 2017

3

1 reference

24 September 2017

137-141

1 reference

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

24 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Multiple sclerosis: diagnostic optimism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

An immunogenetic heterogeneity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Natural history of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Clinical definition for multiple sclerosis treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

The epidemiology of multiple sclerosis: a general overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Clinical parameters and intrathecal IgG synthesis as prognostic features in multiple sclerosis. Part I

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Psychoses following war brain injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Multiple sclerosis presenting with progressive visual failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Multiple sclerosis: update in diagnosis and review of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Multiple sclerosis. The problem of incorrect diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Patterns of blood-brain barrier impairment and clinical features in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Primary progressive versus relapsing remitting multiple sclerosis in Japanese patients: a combined clinical, magnetic resonance imaging and multimodality evoked potential study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

The British Isles survey of multiple sclerosis in twins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

A population-based study of multiple sclerosis in twins: update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

The familial incidence of disseminated sclerosis and its significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Multiple sclerosis: updated risks for relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Low dose oral methotrexate treatment of multiple sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

Cladribine in treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200304

10.1177/135245859600200304

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9345378